GOLDMAN SACHS GROUP INC - 16 Nov 2022 Form 3 Insider Report for NeuroBo Pharmaceuticals, Inc. (MTVA)

Role
10%+ Owner
Signature
/s/ Jamison Yardley, Attorney-in-fact
Issuer symbol
MTVA
Transactions as of
16 Nov 2022
Net transactions value
$0
Form type
3
Filing time
22 Nov 2022, 15:46:00 UTC
Previous filing
17 Nov 2022
Next filing
21 Nov 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding NRBO Common Stock 1,220,502 16 Nov 2022 See Footnotes F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This statement is being filed by The Goldman Sachs Group, Inc. ("GS Group") and Goldman Sachs & Co. LLC ("Goldman Sachs" and together with GS Group, the "Reporting Persons"). Goldman Sachs is a subsidiary of GS Group. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein. On November 16, 2022, the Reporting Persons experienced an increase in their beneficial ownership of Neurobo Pharmaceuticals, Inc. (the "Issuer") to above 10% of the outstanding Common Stock. On November 17, 2022, the Reporting Persons experienced a decrease in their beneficial ownership that reduced their beneficial ownership to below 10% due to a reduction in excess securities borrows.
F2 The Common Stock of the Issuer reported herein as indirectly purchased were beneficially owned directly by Goldman Sachs and indirectly by GS Group.